retlirafusp alfa

News

Hengrui has achieved a milestone in oncology as retlirafusp alfa is approved in China, its first world market, for gastric cancer.

News

Isomab has presented landmark safety data at ESC, clearing the path for next-generation therapies to promote blood vessel growth in CAD.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.